Product Images Imfinzi

This appears to be a drug information label containing important details about how to administer an injection medication via intravenous infusion. The label advises proper storage from 2 to 8 degrees Celsius and cautions against freezing or shaking. It also emphasizes the importance of protecting the drug from light and not using it if the vial seal is broken or missing. The label instructs the pharmacist to dispense a medication guide to each patient and provides a product code and information about the manufacturer, Astrazeneca.*

This table appears to show the probability of OS (overall survival) over time from randomisation (in months) for a group of patients. The patients were possibly divided into two treatment groups: one group received DNFINZI and chemotberspy, while the other group received treatment identified as "e w2". The number of patients at risk (i.e. still alive) decreases over time. The last column of the table is not legible with the given text.*

The text is a mixture of a drug name, dosage information, and instructions for medical personnel. The drug is called "durvalumab" and is administered through an intravenous infusion after dilution. The recommended storage temperature is 2-8°C, and any unused portion should be discarded. There is a note to pharmacists to dispense the medication with an accompanying medication guide for the patient. The text seems to be missing some crucial information and is not sufficient for a comprehensive description.*